Table 2.
Epidemiologic characteristics of the 139 survey respondents
| No. of participants | Profession | Expertise > 10 years | Response rate (%) | |||||
|---|---|---|---|---|---|---|---|---|
| Total | 139 | 100% | PHO | 115 | 82.7% | 122 | 87.8% | 66.8 |
| Pediatrician* | 5 | 3.6% | ||||||
| MD* | 10 | 7.2% | ||||||
| Neuro-Oncol | 1 | 0.7% | ||||||
| Neurosurgeon | 1 | 0.7% | ||||||
| Radiotherapist | 6 | 4.3% | ||||||
| Biologist | 1 | 0.7% | ||||||
| Country of employment | ||||||||
| Germany | 69 | 49.6% | PHO | 52 | 75.4% | 60 | 87.0% | 66.3 |
| Pediatrician* | 5 | 7.0% | ||||||
| MD* | 9 | 13.0% | ||||||
| Country of employment | ||||||||
| Other countries | 70 | 50.4% | PHO | 63 | 90.0% | 62 | 88.6% | 67.3 |
| Neuro-Oncol | 1 | 1.4% | ||||||
| MD* | 1 | 1.4% | ||||||
| Austria | 4 | 2.9% | 80.0 | |||||
| Belgium | 2 | 1.4% | 66.7 | |||||
| Croatia | 1 | 0.7% | 100.0 | |||||
| Czech Republic | 1 | 0.7% | 20.0 | |||||
| Denmark | 2 | 1.4% | 66.7 | |||||
| France | 6 | 4.3% | 54.5 | |||||
| Greece | 2 | 1.4% | 100.0 | |||||
| Hungary | 2 | 1.4% | 100.0 | |||||
| Iceland | 1 | 0.7% | 100.0 | |||||
| Ireland | 1 | 0.7% | 100.0 | |||||
| Italy | 9 | 6.5% | 90.0 | |||||
| Lithuania | 3 | 2.2% | 100.0 | |||||
| Netherlands | 5 | 3.6% | 50.0 | |||||
| Norway | 2 | 1.4% | 66.7 | |||||
| Portugal | 4 | 2.9% | 75.0 | |||||
| Russian Federation | 3 | 2.2% | 100.0 | |||||
| Spain | 6 | 4.3% | 100.0 | |||||
| Sweden | 2 | 1.4% | 50.0 | |||||
| Switzerland | 7 | 5.0% | 100.0 | |||||
| Turkey | 1 | 0.7% | 100.0 | |||||
| United Kingdom | 6 | 4.3% | 29.4 | |||||
The weblink to the survey was sent via e-mail to 126 members of the International Society of Pediatric Oncology Europe-Brain Tumor Group (SIOPE-BTG) and additionally opened by 104 members of the Society of Pediatric Oncology and Hematology in Germany, Austria, and Switzerland (GPOH)
*Not explicitly declared themselves as pediatric hemato-oncologists in the survey, but members of the SIOPE-BTG or GPOH
PHO pediatric hemato-oncologist; MD medical doctor